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The human cardiovascular system is a complex arrangement of specialized structures with distinct functions. The molecular landscape, in-
cluding the genome, transcriptome and proteome, is pivotal to the biological complexity of both normal and abnormal mammalian processes.
Despite our advancing knowledge and understanding of cardiovascular disease (CVD) through the principal use of rodent models, this con-
tinues to be an increasing issue in today’s world. For instance, as the ageing population increases, so does the incidence of heart valve dys-
function. This may be because of changes in molecular composition and structure of the extracellular matrix, or from the pathological process
of vascular calcification in which bone-formation related factors cause ectopic mineralization. However, significant differences between mice
and men exist in terms of cardiovascular anatomy, physiology and pathology. In contrast, large animal models can show considerably greater
similarity to humans. Furthermore, precise and efficient genome editing techniques enable the generation of tailored models for translational
research. These novel systems provide a huge potential for large animal models to investigate the regulatory factors and molecular pathways
that contribute to CVD in vivo. In turn, this will help bridge the gap between basic science and clinical applications by facilitating the refine-
ment of therapies for cardiovascular disease. 2016 The Authors. Published by John Wiley & Sons Ltd.
key words—cardiovascular disease; large animal models; calcific aortic valve disease; aortic stenosis; vascular calcification; Marfan
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INTRODUCTION
The mammalian cardiovascular system is a vast network of
specialized structures and vessels, which allows blood and
other important molecules to be transported throughout the
body. Central to the system is the four-chambered heart that
acts as a muscular pump to permit the movement of blood.
Four cardiac valves ensure that blood flows through the
heart and into the arteries in only one direction 1. The veins
and arteries comprise three concentric tubes: an outer con-
nective tissue layer (tunica externa), a middle smooth mus-
cle cell layer (tunica media), which is thinner in the veins
than the arteries and an inner endothelial cell layer (tunica
intima) 2.
Cardiovascular disease (CVD) is a leading global cause of
morbidity and mortality 3. The American Heart Association
(AHA) reported that CVD accounted for approximately one
in three deaths in the United States in 2011 4. Additionally,
34% of CVD-attributed deaths occurred before 75 years of
age, which was below the present average life expectancy
of 78.7 years 4. According to the World Health Organization
(WHO), some of the top cardiovascular-related causes of
premature death include coronary heart disease, chronic ob-
structive pulmonary disease, and stroke 5.
In recent decades, both invasive and non-invasive thera-
pies of CVD have advanced considerably. This advance-
ment has been facilitated by basic research, and progressed
with clinical studies 6. Nowadays, it is becoming more ap-
parent that understanding biological systems at the basic sci-
entific level is important in order to provide clinicians with
new approaches and tools for the assessment and treatment
of their patients 6.
Within the field of cardiovascular research, new interven-
tional strategies range from experimental procedures for
testing new implantations and devices, to more specific
studies of underlying mechanisms of particular CVDs. In
the development of these strategies and basic research, the
role of animal models of CVD is especially important. This
review aims to look at some of the cardiovascular issues in
today’s world, such as heart valve disease and vascular cal-
cification, the expanding research resources made available
through the use of large animal models and the potential
of novel genetic engineering technologies in this field.
ANIMAL MODELS OF CVDS
Animal models are important for discerning the aetiology
and pathogenesis of human diseases with the purpose of de-
veloping novel disease preventions and therapies 7. Many of
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our achievements on the treatment and management of
CVDs have been made through the use of experimental an-
imal models. These disease models have helped in outlining
the pathogenesis, progression and mechanisms behind
CVDs at the molecular and cellular levels, enabling the de-
velopment of many effective treatment approaches.
A number of models exist to address cardiovascular compli-
cations, such as atherosclerosis and other cardiac diseases,
where similar pathologies have been recreated in different spe-
cies, including large and small animals. Although no model
can entirely replicate the complexities seen in human patholo-
gies, they are crucial in assessing mechanisms of disease, as
well as evaluating novel diagnostic technologies, preventions
and therapies 7,8. Model organisms are used predominantly to
improve human health, and to enable translatable scientific
discoveries with practical applications. Large animals can
facilitate in these goals, as they exhibit disease characteristics
similar to humans, giving mechanistic insight into the biologi-
cal and pathological processes. Additionally, they enable us to
obtain direct information about specific physiological events,
and studies of diseases with respect to a control group are
possible in order to observe the effects of particular variables,
treatments, and modified factors. This is in contrast to human
studies, in which appropriate age and sex matched control
sample groups are often very difficult to obtain.
The current use of small rodents as the main model of hu-
man diseases is widespread, and they are a popular choice of
species for several reasons. They are relatively cost effective
and easy to maintain, and can provide large litters; thus,
studies can be given adequate power by the use of appropri-
ate numbers of animals. The ability to genetically modify
mice through either the ablation or overexpression of a gene
of interest has made them indispensable in teasing apart the
mechanisms underpinning CVD.
Nonetheless, limitations do exist, and significant cardio-
vascular differences are apparent between humans and ro-
dents 9. In light of the important role of inflammation in
several CVDs, differences between species should be con-
sidered. One of the most drastic disparities between humans
and mice is the response to bacterial lipopolysaccharides,
which is five orders of magnitude higher in humans 10. This
contrasting response has been attributed to the differential
composition of mouse serum 11: in mouse blood the pre-
dominant population of leukocytes is lymphocytes, whereas
human blood is neutrophil rich 12. Interestingly, pigs show
greater similarity to humans in this regard, whereby neutro-
phils are also the predominant circulating blood cell popula-
tion 13. Furthermore, during delayed-type hypersensitivity
testing neutrophils surround the antigen followed by an in-
flux of mononuclear cells resulting in a predominantly
macrophage and T-cell lesion in humans 14. However, in
mice a comparable test results in a predominantly neutrophil
lesion 15. The small size of rodents makes them easy to han-
dle and offers key advantages such as the application of intra
vital microscopy in in vivo inflammatory studies 16. Addi-
tional imaging techniques are frequently complicated by
the smaller size, and smaller volumes of circulating blood
also make repeat sampling challenging in these studies.
Although employing large animals may involve higher
costs, because of their size and husbandry needs when com-
pared to smaller models, their importance in the field of hu-
man diseases is evident as they have more cardiovascular
similarities in terms of anatomy, physiology and size to
humans than the rodent species. The ability to apply
human-like settings to model animals increases the chances
of bench findings translating to effective treatments. This
includes using human clinical equipment and surgical tech-
niques. For example pigs have been used for decades to develop
surgical procedures for implementation in humans, and pig
valves are used in some cases of human valve failure 17. In ad-
dition, their larger size provides a better choice for imaging and
tissue engineering studies. Studies utilising large animalmodels
can illuminate the biological pathways and mechanisms to fa-
cilitate the refinement of CVD therapies. Despite these advan-
tages, there are significant challenges to the use of large
animal models in addition to costs. These include the availabil-
ity of antibodies and assays specific to these species. However,
with increasing use of large animals the increased demand
should bring about an increase in availability of these products.
Compared to the mouse there are few transgenic large animals.
However, new gene editing technologies allow the establish-
ment of precise and efficient gene editing techniques that, as de-
scribed later in this review, should enable the generation of
tailored large animal models of human disease.
THE CARDIOVASCULAR SYSTEM, DISEASES AND
INSIGHTS
Valvular heart disease (VHD)
Valvular heart disease (VHD) encompasses a range of car-
diovascular conditions, accounting for 10–20% of all car-
diac surgeries in the United States 18. As the ageing
population continues to increase, so does the prevalence of
patients with degenerative valve disorders 4. In addition,
the morbidity and mortality rates of open-heart surgery,
the main approach taken for patients with VHD, can be
high, providing challenges to reconstructive procedures 6.
Better understanding of the function of the valves and the
perturbations that lead to disease is imperative to the future
provision of surgical and therapeutic interventions.
There are four cardiac valves: the mitral (bicuspid) valve
and aortic semilunar valve on the left side of the heart, and
the tricuspid valve and pulmonary semilunar valve on the
right side. The heart valve leaflet structure consists of cellu-
lar and extracellular components. Extracellular components
include collagen, glycosaminoglycans (GAGs) and elastin
present in the three layers of the valve: the fibrosa,
spongiosa and ventricularis, respectively (Figure 1) 19–22.
Valve surface endothelial cells (VECs) and the inner valve
interstitial cells (VICs) are the principal cell types found in
the cardiac valves 19,20,23.
Over 60% of valve disease mortality is because of semilu-
nar valve dysfunction, especially of the aortic valve, with
approximately 50 000 valve replacement or repair proce-
dures reported each year in the USA 24. Semilunar valve
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diseases affect all ages, from congenital valve defects in ne-
onates and children, to the increasing number of elderly with
calcified valves 24. These dysfunctional heart valves most
often require surgical replacement using mechanical or
bioprosthetic valves which are prone to failure over time
from structural or thrombosis-related problems 24.
Although many studies into valvular biology use adult
aortic valve tissues and cells from either humans or animals,
it is clear that the subject’s age is important in order to assess
age-specific pathologies and conditions 24. An earlier study
reported numerous age-related changes in the extracellular
matrix (ECM) composition and mechanical properties of
the aortic valves, in addition to valve cell phenotypes 24.
The ECM is the cell-synthesized structural backbone of con-
nective tissue. It provides a structural frame for
mesenchyme-derived tissues, in addition to regulating inter-
actions between numerous growth factors and cell surface
receptors 25,26. Within the ECM are elastic fibres, collagen
fibrils and microfibrils, which contain components including
elastin, collagen and the fibrillins 27. In the cardiovascular
system, this complex meshwork also ensures normal cardio-
vascular function by providing the biomechanical character-
istics of the blood vessel walls 27. Substantial tissue growth
and remodelling occur before adulthood 24. In foetal devel-
opment, trilaminate ECM structures or highly aligned elastin
and collagen that are evident in adult valves are not yet pres-
ent in the aortic valves 24. The ECM is also an essential
component in the cardiac valves, where its disruption has
been reported in valve diseases, as will be mentioned later
on. As valvular diseases continue to increase in the elderly
population, improving our understanding of how valve cells
and the ECM functions change throughout ageing is crucial,
as well as distinguishing their responses to surrounding en-
vironments in various physiological states, such as those
pertaining to vascular calcification.
Figure 1. Simplified cross section of the aortic valve showing progression of aortic valve calcification. Valve endothelial cells (VECs) line the valve leaflet
surface. The inner layers of the valve consist of the fibrosa, spongiosa and ventricularis. The principal cell type within each layer is the valve interstitial cells
(VICs). The fibrosa contains collagen (Types I and III), the spongiosa contains glycosaminoglycans (GAGs) and the ventricularis—elastin fibres. In calcific
aortic valve disease (CAVD), often the fibrosa layer becomes calcified and thickened. This may be because of lipid deposition and inflammatory processes
which trigger the osteochondrogenic transdifferentiation of VICs. Calcium deposition then occurs, forming bone-like material as neovascularization around
the calcified lesions and remodelling of the extracellular matrix occurs. This results in the formation of calcified nodules and the thickening of the valve leaflet
Figure 2. Simplified diagram showing potential RANK/RANKL/OPG involvement in bone remodelling and in vascular calcification. Receptor activator of
nuclear factor kappa-B ligand (RANKL) from osteoblasts or endothelial cells binds to the Receptor Activator of Nuclear Factor kappa-B (RANK) of osteoclast
precursors, or vascular smooth muscle cells (VSMCs). This leads to differentiation into mature osteoclasts in the bone, which are involved in bone resorption,
whereas in vascular calcification, VSMCs undergo a phenotypic transition into osteochondrogenic cells that can deposit mineralized matrix. Osteoprotegerin
(OPG) is the decoy receptor for RANKL, and a potential inhibitor for mineralization
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The function of the cardiac valves is of crucial impor-
tance. However, the aortic valve is especially vital as it is
a partition between the left ventricle and the aorta, at the
level where the coronary arteries arise. Therefore, significant
clinical complications occur when congenital defects and
chronic disorders relating to the aortic valve are present, as
current diagnostic and therapeutic strategies are inadequate.
Although there have been major advancements in the last
decade or so in valvular biology, there are still many pieces
to be found to form a clear picture of the pathological mech-
anisms that impair valvular function.
Models of calcific aortic valve disease (CAVD)
Calcific aortic valve disease (CAVD) is a progressive disor-
der involving valve leaflet thickening (aortic sclerosis), lead-
ing to severe calcification with impaired leaflet motion
(aortic stenosis) 28. Aortic stenosis is a major form of
CVD, along with hypertension and coronary artery disease,
in the Western world 18,29. Almost 30% of adults above
65 years have aortic stenosis, and approximately 50% in
those above 85 years 30,31. It develops from progressive leaf-
let calcification, causing gradual restriction of the opening of
the leaflets 18. Aortic stenosis shares similarities with athero-
sclerosis, for example, their risk factors include age, diabe-
tes, hypertension, obesity, increased low-density
lipoprotein (LDL) cholesterol and lipoprotein(a), as well as
smoking 18,31–34. Pathological studies of human aortic ste-
nosis have identified valvular lesions containing inflamma-
tory cells and calcific deposits similar to those found in
atherosclerotic plaques 33. Once symptoms develop as a re-
sult of increasing stenosis severity, including angina and
heart failure, there is a higher risk of sudden death with
the average survival of only 2–3years 18,35.
Studies assessing the biological and structural changes in
aortic valves have predominantly used mouse models. Tech-
niques used have included staining for calcium deposition,
quantitative real-time PCR (qRT-PCR) to examine changes
in mRNA levels for specific genes, protein quantification
and enzymatic activity 36. To date, there are reports of pro-
osteogenic signalling cascades thought to contribute to the
initiation and progression of aortic stenosis. Signalling mol-
ecules include bone morphogenetic proteins (BMPs),
Wnt/β-catenin and transforming growth factor-β (TGF-β) al-
though the role of TGF-β in osteogenic signalling is not
clear 36. The RANK/RANKL/OPG pathway is also thought
to be involved in the calcification process, which involves
complex interactions between receptor activator of nuclear
factor kappa B (RANK), RANK ligand (RANKL), and oste-
oprotegerin (OPG) (Figure 2) 36,37. Matrix remodelling may
also be involved in the expansion of calcified plaques and
pro-inflammatory processes, through alterations in matrix
metalloproteinases (MMPs) and elastin fragments produced
by cathepsins 36. Furthermore, the NOTCH1 pathway has
been implicated as a regulator of valve calcification, through
the repression of the osteoblast transcription factor Runt-
related transcription factor 2 (RUNX2) (Figure 3) 38.
This suggests an inhibitory role of NOTCH1 in valvular cal-
cification. Additionally, a number of ECM proteins have
been found to have roles in CAVD including collagen, elas-
tin and GAGs, where changes in their expression have
impacts on cellular processes, and also cause valve leaflet
thickening 39.
Pro-mineralization processes can also be regulated by cir-
culating calcification inhibitors, including matrix γ-
carboxyglutamic acid or matrix Gla protein (MGP), which
inhibits BMP signalling 40. CAVD patients were also found
to have less circulating MGP 41. Another circulating inhibi-
tor of calcification, Fetuin-A, binds clusters of calcium and
phosphate, preventing their uptake into cells 42. Circulating
levels of Fetuin-A have been shown to be reduced in perito-
neal dialysis patients displaying rapid development of val-
vular calcification 43. Furthermore a cross-sectional study
of 970 patients with coronary artery disease found an in-
verse relationship between circulating Fetuin-A levels and
mitral and aortic valve calcification 44. Aortic stenosis in pa-
tients with CAVD has also been associated with increased
plasma levels of potential promoters of calcification, such
as the non-collagenous bone matrix protein osteopontin
(OPN), a pro-inflammatory glycoprotein that regulates cal-
cium deposition by osteoblasts 45.
The mechanism for CAVD development is similar to
skeletal bone formation (ossification). CAVD progression
is regulated by cells within the valve that develop an
osteoblast-like phenotype 46. Within calcified aortic valves,
markers of bone differentiation have also been discovered,
including RUNX2, OPN, osteocalcin (OCN) and bone
sialoprotein 46,47. RUNX2 expression is a marker for osteo-
blast differentiation, whilst OCN is a late marker of calcifica-
tion in osteoblastogenesis 48,49. Intriguingly, ossification, the
Figure 3. Simplified diagram showing potential NOTCH1 involvement in vascular calcification. NOTCH1 signalling may be involved in the inhibition, as
well as the promotion, of vascular calcification through additional factors. Black arrows indicate stimulatory effects, whilst red lines indicate inhibitory effects
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active process of bone tissue repair and remodelling, is ob-
served in end-stage VHD 50. In addition to the presence of
mature lamellar bone and infiltration of inflammatory cells,
BMPs -2 and -4 have been found in calcified valves 50.
BMP-2 is a potent osteogenic differentiation marker, a mem-
ber of the TGF-β superfamily, and has been found to be in-
volved in calcification following the repression of
NOTCH1 signalling in sheep aortic VICs 51. Mutations in
NOTCH1 have been linked with the presence of aortic valve
calcification in human and mouse studies, although the dis-
ease was much milder in the latter 51. A recent study of
NOTCH1 in human aortic VECs found that this factor posi-
tively regulatedMGP 52. Shear stress was simulated bymedia
flow conditions in vitro and was found to activate NOTCH1
expression 52. Because MGP can inhibit BMPs, this may
be the route through which NOTCH1 represses BMP-2. In-
triguingly, it has been reported that NOTCH1 induces the dif-
ferentiation and calcification of vascular smooth muscle cells
(VSMCs) through a BMP-2 driven mechanism (Figure 3) 51.
However, the role of NOTCH1 in the calcification of valves
and vessels remains to be fully understood, and requires fur-
ther investigation.
The mechanisms underpinning the process of valvular
calcification have yet to be fully elucidated. However, an
‘initiation’ and ‘propagation’ phase has been described 53.
It may be that in response to valvular damage, such as
through endothelial disruption via shear stress, lipid deposi-
tion and inflammation occur, which subsequently triggers
calcification (Figure 1) 54–56. Neovascularization was also
found in calcified valves, suggesting that this is important
in CAVD 50, with new vessels commonly found in areas
of inflammation around calcified deposits 57. Haemorrhage
has been associated with neoangiogenesis, macrophage in-
filtration and accelerated disease progression in patients
with advanced aortic stenosis 58. Nevertheless, the roles of
the factors and pathways involved in VHDs and other
CVDs, including those briefly mentioned above, remain un-
clear. More information into the early stages of disease ini-
tiation and progression is required to understand the
mechanisms of CAVD.
Currently, the only option to treat CAVD is through valve
replacement surgery. This reflects our lack of understanding
of the early pathobiological processes, even though later
stages of the disease are well described. Additionally, as
the implicated regulators of ectopic calcification are required
for normal bone mineralization, establishing a therapeutic
strategy that does not affect bone is crucial. And so,
uncovering the factors and mechanisms that are important
during the initiation and progression of these diseases facil-
itated by animal models is required for developing such
treatments and interventions. Many studies into aortic steno-
sis utilize the mouse as a model 36. However, the size of the
aortic valves limits the amount of material available for ex-
amining the molecular mechanisms behind CAVD. Al-
though diseased human valve samples can be obtained
relatively easily, acquiring healthy samples is nearly impos-
sible. In contrast, healthy valve samples from animals are far
more accessible, can be used as a healthy control and can
provide a source of valve cells that can be isolated for exper-
imentation 59,60.
Large animal models of cardiovascular dysfunction.
Models of CAVDs (Table 1) have been established in a
range of animals including the pig, rabbit and dog (reviewed
in 61–66). For cardiac valve specific studies, aortic valve
cells, predominantly the VECs and VICs, have been isolated
and cultured from various large animals, including the pig,
cow, sheep and dog 60,62,67–73. A rabbit model of hyperten-
sion was used to study mild aortic valve stenosis 74. In this
study, echocardiography was used to assess the morphology
and function of aortic valves, as well as left ventricular mass
74. This study demonstrated that hypertensive rabbits tended
to show reduced aortic valve area and increased valve thick-
ness. Although the rabbit is often used to study VHD, the
atherosclerotic lesions that are formed do not simulate
those found in humans, limiting its suitability as a model
of CVD 66.
The pig can develop spontaneous lesions in the vascula-
ture and cardiac valves, and has been widely used to study
atherosclerosis 75. The porcine cardiovascular system shares
many similarities with that of humans, including heart anat-
omy and tri-layered aortic valve leaflets, as well as similar
lipid profiles and lipoprotein metabolism 76,77. These attri-
butes highlight the pig as an ideal model for CAVD. Cur-
rently there are a number of research groups working to
characterize cellular and molecular components in porcine
valves. For example, aortic and ventricular side aortic VECs
from adult male pigs have been compared, using microarray
and qRT-PCR to measure gene expression 78. In this study,
side-specific expression differences were found between the
aortic and ventricular VECs 78. Interestingly, higher expres-
sion was noted in the aortic side of the valve of genes asso-
ciated with vascular calcification and skeletal development,
such as BMP-4 78. Lower expression of factors shown to in-
hibit ectopic calcification was also observed in the aortic
side VECs, including OPG, C-type natriuretic peptide
(CNP) and chordin (an inhibitor of the osteoinductive activ-
ity of BMPs) 78. This may permit aortic side-specific vulner-
ability to calcification. In addition to this, greater expression
of antioxidative genes and an absence of differential expres-
sion of pro-inflammatory factors on the aortic side suggests
potential protection in the normal valve against lesion devel-
opment and inflammation 23,78.
A porcine model of early aortic valve sclerosis has also
been assessed 61. In this investigation, pigs were fed either
a standard or high fat/cholesterol (HF/HC) diet for 2–
5months. Swine fed on the HF/HC diet developed signifi-
cantly thicker lesions on the aortic side of coronary aortic
valve leaflets, with histologically opaque regions consisting
of proteoglycans, collagen and elastin, within the fibrosa
layer as similarly observed in early human CAVD 61. In-
creased expression of osteochondrogenic markers including
SRY (sex determining region Y)-box 9 (SOX9) and Msh
Homeobox 2 (MSX2) has been observed in dense
proteoglycan-rich lesion onlays with the HF/HC diet 61 as
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have complicated atherosclerotic lesions with ectopic calci-
fication 77. Furthermore, there appears to be a higher suscep-
tibility of the aortic side of the aortic valve leaflet to
calcification and disease lesions 79. Additional investiga-
tions are required to identify the side-specific components
and mechanisms that may underlie these observations in
the aortic side of the leaflets.
As inflammation plays a key role in the initiation and de-
velopment of valve calcification, a gene profile of porcine
aortic VICs (PAVICs) under elevated pressure was gener-
ated to study expression of inflammatory genes, with the re-
sults showing similarities to those seen in CAVD 80. The
ECM protein matrix metallopeptidase 3 (MMP3) and pro-
inflammatory cytokine interleukin 6 (IL-6) were amongst
those found to be upregulated in this study 80. Furthermore,
the inflammatory gene network revealed was associated
with the upregulation of tumour necrosis factor alpha
(TNFα) 80.
The similarities of early stages of aortic stenosis to athero-
sclerosis through the shared processes of lipid deposition,
inflammation and calcification originally led to the idea that
statins may be beneficial in CAVD patients. In clinical trials
in patients, however, statin therapies surprisingly failed to
produce reduction in the progression of aortic stenosis, de-
spite significant decreases in serum LDL cholesterol levels
81–83. While both lipid deposition and inflammation may
be important processes in aortic stenosis, it may be likely
that the accumulation and propagation of calcium crystals
drives disease progression. Future therapies against aortic
stenosis may involve lipid-lowering and calcification
inhibiting effects, such as through a combination of statins
and mineralization inhibitors.
Vascular calcification and models
Vascular calcification is a disease of abnormal mineral
metabolism, in which calcium phosphate crystals, in the
form of hydroxyapatite (HA), are deposited in blood ves-
sels 84–86. It is a hallmark feature in ageing, hypertension
and atherosclerosis 86–88. For example, coronary artery cal-
cification (CAC) predicts atherosclerotic burden in the arter-
ies, which can be measured by computerized tomography
(CT) 4. The presence of CAC is an indicator of the presence
of atherosclerotic plaque 4. The pathological process of vas-
cular calcification is a major, independent risk factor of car-
diovascular mortality 85.
Calcification can develop in the tunica media and/or the
intima layers of blood vessels, resulting in the thickening
and loss of elasticity of arterial walls 86,89. Intimal calcifica-
tion is typically found in large vessels and coronary arteries,
and it involves intimal hyperplasia and atherosclerosis 90.
For medial calcification, dense calcium sheets form in the
tunica media between VSMCs, which have been found to
contain bone components, including bone trabeculae and os-
teocytes 90. The latter form of calcification is most fre-
quently exhibited in distal vessels of patients with
advanced ageing, diabetes and kidney failure 90.
Other than the blood vessels, calcification of the vascular
system can also be found in the myocardium and the cardiac
valves (as described previously), and ectopic calcification in
these regions is associated with clinical symptoms 84,91. Ec-
topic vascular calcification impairs blood flow and blood
vessel compliance, making it an independent and strong pre-
dictor of death through cardiovascular risks, such as arterial
hypertension, left ventricular hypertrophy and cardiomyopa-
thy 89,92,93.
Vascular calcification can be induced through the loss of
mineralization inhibitors, as well as the initiation of ectopic
bone formation 94. This process shares many similarities
with physiological bone mineralization, where there are pro-
teins associated with bone formation being generated by
VSMCs 90,95,96. Extensive investigations in the last two de-
cades have shown that pathological vascular calcification is
a tightly regulated process, where vascular cells may acquire
Table 1. Examples of large animal models of calcific aortic valve disease
(CAVD)
Animal model Key findings Reference
Pig Aortic side valve
endothelial cells (VECs)
may be more susceptible
to calcification.
Sider et al. 2014 61
High fat/high cholesterol
(HF/HC) diet induced
thick proteoglycan lesions
in the fibrosa layer (aortic
side of valve) in an up
to 5-month study.
Simmons et al. 2005 78
HF/HC diet induced
calcification in atherosclerotic
lesions in an up to 48-week
study.
Gerrity et al. 2001 77
Rabbit Mild aortic valve stenosis in
hypertensive rabbits,
increased valve thickness and
inflammation nodules,
hypertrophy of valve after
4 months.
Cuniberti et al. 2006 74
High cholesterol diet
for 20 and 40 weeks,
atherosclerotic lesions
present in aortic valves, with
increased lipid deposition,
inflammatory cell
infiltration, osteopontin
(OPN) deposition, changes
in collagen and elastin
distribution, and
mineralization.
Cimini et al. 2005 288
Dog Canine aortic valve interstitial
cells (VICs) spontaneously
formed apparent calcified
nodules containing
hydroxyapatite within
2–3 weeks.
Mohler et al. 1999 62
Sheep The inhibition of bone
morphogenetic protein 2
(BMP-2) by Notch1
signalling in sheep aortic
VICs is a potential
mechanism by which aortic
valve calcification is subdued.
Nigam and Srivastava
2009 289
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osteoblast-like functions 86. Vascular cell calcification can
be stimulated by the same group of genes as those expressed
during bone formation 97. Atherosclerotic plaque calcifica-
tion essentially involves the same biological processes as
in normal bone formation 98. Studies have characterized
the mineral element of vascular calcification where the cal-
cium deposits primarily exist in the form of HA, again, sim-
ilar to that seen in bone 99–102. In addition, the expression
of numerous key mediators of bone formation and bone
structural proteins are present, such as MGP, OPG and
OPN 101,103–106. Nonetheless, although the sequence of
events leading to normal bone formation is well known, it
is still unclear through which specific mechanisms vascular
calcification occurs 86,98. Calcification of atherosclerotic
plaque has been attributed both beneficial and deleterious
effects 107. Mathematical models predict that micro-
calcifications of the thin fibrous cap of atherosclerotic
plaque local stress concentrations that lead to interfacial
debonding and plaque rupture 108,109. And that the effect
of micro-calcification is increased with decreasing cap thick-
ness 110. In agreement with these predictions, histological
examinations of ruptured human lesions found that rupture
commonly occurs in areas of maximum circumferential
stress 111. Rupture in sites of lower stress suggests
heterogeneity of plaque constituents, resulting in local
stresses 110,111. However, post mortem in vitro imaging of
human atherosclerotic lesions found that microcalcification
of the fibrous cap was rare 108. Analysis of both stable and
ruptured human lesions found that the lipid content of the le-
sions correlates with maximum circumferential stress and
not with calcification 112.
Increased calcium levels promote mineralization and influ-
ence various mechanisms in VSMCs that result in increased
susceptibility to matrix mineralization 84. Elevated calcium
and phosphate induce VSMC calcification in vitro, causing
VSMC phenotypic change 85,113,114. In a calcified environ-
ment, VSMC populations contain cells that undergo pheno-
typic transitions to osteocytic, osteoblastic and chondrocytic
cell types 86,115. This phenotypic change is because of loss of
VSMC markers and the gain of osteochondrogenic markers,
including alkaline phosphatase (ALP), OPN and RUNX2
86,116,117. Moreover, ectopic calcification may be a result of
the loss of mineralization inhibitors. These include
ectonucleotide pyrophosphatase/phosphodiesterase 1
(ENPP1), ATP-binding cassette transporter subtype 6
(ABCC6), the CD73 ectonuclease and fibrillin 1 (FBN1) 118.
It has yet to be discerned whether human vascular calcifi-
cation causes, or is caused by, the expression of bone-related
genes. Therefore, focus on the very early stages of ectopic
calcification is critical. Explorations into this may be possi-
ble through the use of animal models, where disease pro-
gression and the underlying causes can be examined.
A number of popular rodent models exist. Non-uraemic
models include transgenic mice that are deficient in known
calcification inhibitors, such as Fetuin-A 119, MGP 120 and
OPG 121. Vascular calcification can also be induced in rats
by high doses of warfarin, which induces rapid calcification
of vascular elastic lamellae and aortic valves 122. These rats
are phenotypically similar to MGP knockout mice, suggest-
ing similarity in underlying mechanisms 122. Uraemic
models of vascular calcification include the 5/6 nephrec-
tomy rat. In this animal, renal failure is modelled by total
nephrectomy of one kidney and the ligation of 2/3 of the
extra-renal branches of the renal artery of the contralateral
kidney 123,124. These rats develop mild calcification predom-
inantly in the aortic arch 125. This calcification is exacer-
bated and accelerated by a high phosphate diet 126, or 1,25
(OH)2 vitamin D3 treatment 127–129. Uraemia can also be in-
duced with excessive dietary adenine, of which a metabolite,
2,8 dihydroxyadenine, precipitates in the kidney inducing
renal failure 130. When fed a high phosphate diet following
a high adenine diet, rats develop severe vascular calcifica-
tion 131. While several rodent models are presently
employed in the field, a robust large animal model of vascu-
lar calcification has yet to be established. A brief summary
of large animal vascular calcification models utilized to date
can be found in Table 2.
A number of vascular calcification investigations have in-
volved studies of the ENPP1 gene. Loss-of-function muta-
tions in the ENPP1 gene, which encodes ENPP1, also
known as plasma cell membrane glycoprotein 1 (PC-1),
have been associated with rare human genetic disorders
132–135. Mutations of this gene are linked with a genetic de-
ficiency in pyrophosphate levels causing a life-threatening
disorder known as Generalized Arterial Calcification of In-
fancy (GACI), a rare autosomal recessive disease character-
ized by arterial calcification, fibrosis and stenosis, which
leads to premature death in neonates 84,93,132,134,136,137. As
a recessive disorder, the most severe mutations are those that
associate with the loss of enzymatic function 93. The signif-
icance of ENPP1 mutations is seen in infants with GACI,
who often die with extensive vascular calcification afflicting
nearly all arterial beds, including the coronary arteries 93.
The genetically engineered Enpp1 null mouse model has
been used extensively to investigate medial aortic calcifica-
tion. However, the degree of calcification in this model is
significantly milder than in affected patients. Therefore,
there is a clear need for a more physiologically comparable
large animal model to allow for the development of targeted
therapeutic treatments for this devastating rare disease.
Reports of calcification in large arteries of racehorses
have been made, including the aorta, pulmonary artery and
carotid arteries 138–140. Arroyo et al. (2008) investigated
the prevalence, distribution and severity of vascular calcifi-
cation in both young adult Thoroughbred and Standardbred
racehorses. This study showed material consistent with HA,
found in vascular calcification, to be present in calcified le-
sions. Microscopic evaluation revealed thinned, fragmented
and calcified elastic fibres in the tunica media of the pulmo-
nary arteries, which were encompassed by dense collagen
matrix 141. Furthermore, both breeds and sexes appeared to
be similarly affected 141. Studies using these horses may
be useful for human calcification research, although it is im-
portant to note that calcification can be found in relatively
early ages in horses (below 5years of age), especially in
those with a racing background 139. What contribution
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training and athleticism contribute to these changes is not
known, but horses do develop heart valve changes as they
progress through training programmes. Ectopic calcification
occurring without experimental induction may make the
horse a useful model of disease progression, as well as tissue
being available from those horses that are euthanized.
At present, there are a limited number of medical ap-
proaches with the potential to treat or prevent the progres-
sion of vascular calcification and other associated
conditions, such as aortic stenosis. An example is the use
of the bisphosphonate etidronate, which is currently used
for the treatment of GACI 142. Bisphosphonates are strong
inhibitors of osteoclast activity, and are widely used in clin-
ical practice to prevent bone loss associated with conditions
such as osteoporosis, Paget’s disease and metastatic bone
disease 143. The prolonged use of etidronate can have unde-
sirable effects, such as severe skeletal toxicity as reported in
a 7-year-old GACI patient 144. Because of this, the use of et-
idronate requires close monitoring when administered.
A more recent study describes a potential treatment for vas-
cular calcification using enzyme replacement therapy 145.
Daily subcutaneous administration of ENPP1-Fc, a soluble, re-
combinant protein with the extracellular domain of ENPP1
fused to the fragment crystallisable (Fc) region of human im-
munoglobulin G1 (IgG1), was effective against GACI in a
mouse model 145. This very promising preclinical study may
be the first step to clinical trials with enzyme replacement ther-
apy in GACI patients.
Aortic dysfunction and FBN1 in Marfan syndrome
Diseases of the aortic root and ascending aorta are frequent
causes of aortic regurgitation. Aortic regurgitation can be a
consequence of abnormal aortic leaflets, as well as structural
defects in the aortic root and annulus 18. Various congenital
faults can lead to aortic regurgitation, for example Marfan
syndrome (MFS, OMIM 154700), which is an autosomal
dominant connective tissue disorder 18,27. Mutations of the
FBN1 gene are linked with aortic aneurysms and elastic fi-
bre calcification observed in patients with MFS 26,27,146.
The fibrillin proteins, predominantly FBN1, are the major
structural components of the 10-nm microfibrils of the
ECM 147,148. They are also involved in regulating the bio-
availability of TGF-β. FBN1 is a 350-kDa glycoprotein,
which polymerizes and aggregates to form flexible extracel-
lular microfibrillar structures 27.
Patients with MFS show a broad range of cardiovascular
defects. These include thoracic aortic aneurysms that result
in aortic dissection, rupture or both 149. Dilatation of the root
of the aorta leads to failure of aortic valve occlusion
resulting in valve insufficiency. Additionally, MFS can in-
volve dysfunction of the mitral valve (myxomatous thicken-
ing, prolapse and regurgitation), and medial degeneration
morphologically similar to that observed during ageing, in
idiopathic aortic aneurysms, and in sufferers of aortic valve
disease and hypertension 27. Prophylactic treatment with
beta blockers and angiotensin II receptor antagonists (for ex-
ample losartan) has proved effective in reducing the rate of
Table 2. Examples of large animal models of vascular calcification
Animal
model Key findings Reference
Pig Substantial expression
of ectonucleoside
triphosphate diphosphohydrolase
1 (eNTPD1, CD39)
and ecto-5′nucleotidase
(e5NT, CD73) in aortic
valve interstitial cells
(VICs) and valve endothelial
cells (VECs)—may be
important in valves. Both factors
influence extracellular
nucleotide
concentrations, thus may
be important in valve pathology.
Kaniewska
et al. 2014 19
Horse Sporadic calcification of
large arteries (in the tunica
media) in racehorses mainly
observed in the pulmonary artery
(also in aortic, pulmonary and
carotid trunks). Observed
disorganized collagen
and elastin fibres, and
presence of chondrocyte/
osteoblast-like cells.
Analysis revealed the
mineral found was
consistent with hydroxyapatite.
Arroyo et al.
2008 141
Cow Bovine aortic smooth
muscle cell (BASMC)
calcification induced with
β-glycerophosphate. Results
found mineral deposition in
basal matrix of multilayered areas,
presence of extracellular
matrix vesicles, calcifying
collagen fibrils and calcified
nodules. Osteopontin (OPN)
inhibited calcification dose-
dependently, but did not inhibit
alkaline phosphatase activity or
decrease phosphorus
levels in culture medium.
Wada et al.
1999 290
BASMC calcification
induced with
β-glycerophosphate or
inorganic phosphate.
Found increased mRNA
expression of decorin
(protein expressed in
skeletal tissues), and
overexpression and
supplementation of
exogenous decorin with
calcification medium
increased BASMC mineralization.
Fischer et al.
2004 291
BASMC calcification induced
with inorganic phosphate.
Tropoelastin potentially inhibits
calcium deposition in the
cultured BASMCs through
interactions with elastin
binding protein (EBP).
Wachi et al.
2004 292
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aortic dilatation and hence aortic valve dysfunction 150, al-
though there are no treatments for the underlying defect in
the FBN1 protein.
Cattle have been established as a model of human MFS.
There are a number of spontaneous FBN1 mutations in cat-
tle, resulting in a condition that shares many of the clinical
and pathological manifestations of human MFS 151–153. Di-
minished expression of fibrillin has been found in cultured
bovine MFS dermal fibroblasts and BASMCs, similar to
the findings in human MFS, and pulse-chase metabolic la-
belling experiments verified decreased incorporation of
fibrillin into the ECM 154. Mutations in FBN1 have also
been detected in cattle afflicted with MFS, with similar clin-
ical features as observed in human MFS 153,155.
The FBN1 protein is suggested to be a potential inhibitor
of vascular calcification, because mice with a knock-out of
FBN1 displayed ectopic calcification 156,157. A large animal
in vitro study with cultured bovine aortic smooth muscle
cells found that with accelerated calcification the expression
of FBN1 was reduced 158. These findings may suggest path-
ological interactions between MFS and vascular calcifica-
tion, adding to the complexity of the calcification process.
A related condition is bicuspid aortic valve (BAV) which is
the most common congenital valve abnormality, with an
incidence of around 1% 159. This condition is responsible for
nearly 50% of surgeries for isolated severe aortic stenosis 160.
Although the phenotype is extremely variable, BAV can be
familial, with some cases resulting frommutations inNOTCH1
38,161,162. The bicuspid valve undergoes age-associated calcifi-
cation similar to the tricuspid valve, but at a younger age, so
that most BAVs have significant calcification by the time the
individual reaches 40years of age 163. In mouse models,
BAV has been associated with Nos3, Gata4, Gata5, Gata6
and Nkx2.5 mutations 160,164. Patients with BAV are also at
risk of thoracic aneurysms, and abnormalities of FBN1 protein
have been demonstrated in the VSMCs of BAV aorta 165.
ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disease, and af-
fects medium to large sized arteries 166,167. It is a major
CVD, which can often lead to stroke, myocardial infarctions
and peripheral vascular disease in humans 166. Various ani-
mal models have been developed and have greatly contrib-
uted to the understanding of this disease. Large animal
models of atherosclerosis have been generated, including
the rabbit, pig, goat and non-human primates 166,168.
Initially, atherosclerotic lesions consist of non-protruding
fatty streaks composed of lipid loaded macrophages known
as foam cells. As the lesion progresses, VSMCs switch to a
proliferative synthetic phenotype, which produces excessive
amounts of collagen. As macrophages, foam cells and
VSMCs accumulate, the lesion intrudes into the lumen caus-
ing disturbed flow. This disturbed flow exacerbates endothe-
lial dysfunction, further provoking the lesion. The increased
involvement of VSMCs, along with extracellular accumula-
tion of oxidized LDL and necrotic cell debris, results in
structural weakening. Vulnerable lesion rupture results in
thrombosis of the vessel and ischemia of the downstream
tissue 169,170.
Atherosclerosis shows a tendency to develop in areas of
disturbed or low shear stress, such as bifurcations and curva-
tures. Indeed, turbulent flow causes endothelial dysfunction
in vitro 171. Hyperlipidaemia is also an important factor in
the development of atherosclerosis. The causal relationship
between LDL and atherosclerosis has been extensively stud-
ied 169,170,172–175.
The ideal model of atherosclerosis would develop lesions
that progress through all stages of the disease, from fatty
streak development to unstable plaque rupture. Murine
models offer several advantages in general as stated above.
For the study of atherosclerosis, the most commonly cited
advantages are the short time frame of plaque development,
and the comparative ease of genetic manipulation. Wild type
mice, however, rarely develop atherosclerosis. Unlike
humans, the major circulating lipoprotein in mice is HDL,
rather than LDL, which is the key player in atherosclerosis
progression in humans. Additionally, mice lack cholesteryl
ester transfer protein (CETP) 176, exacerbating the resistance
of these animals to atherosclerosis. CEPT facilitates the ex-
change of cholesterol and triglycerides between HDL and
Apo lipoprotein B, simultaneously decreasing HDL while
increasing LDL 177. Clinically, low CETP activity is associ-
ated with decreased CVD risk 177. Overcoming the
atheroresistant phenotype of mice requires genetic manipu-
lation of their lipoprotein metabolism to produce a more
proatherogenic phenotype. The two most commonly used
models are the Apo lipoprotein E deficient (ApoE/) mice
and the LDL receptor deficient (LDLR/) mice.
ApoE is produced by the liver and macrophages and is in-
corporated into circulating lipoproteins. Through binding of
LDLR and LDLR related protein ApoE mediates the clear-
ance of LDL and very low density lipoprotein (VLDL) from
the circulation 178. Complete deficiency of ApoE in humans
is rare. However, the ApoE2 isoform binds LDLR poorly
and has a high prevalence in patients with congenital type
III hyperlipoproteinemia 179–181. The genetic ablation of
ApoE in mice results in significantly increased circulating
VLDL 182,183. These mice reliably and rapidly develop ath-
erosclerotic lesions; as a result, they have been widely
employed in the study of atherosclerosis 182,183. Despite
their usefulness and reliability, the predominant circulating
lipoprotein in these mice is VLDL, not LDL, which like
wild type mice is markedly different to humans. These ani-
mals are also dramatically hyperlipidaemic when fed a chow
diet 183. This hyperlipidaemia is greatly exacerbated when
fed a high fat diet 183. ApoE has also been demonstrated to
possess immuno-regulatory, anti-inflammatory and antioxi-
dant properties 184–187. In light of the role that low chronic
inflammation plays in the progression of atherosclerosis,
the rapid lesion progression, extreme hyperlipidaemia and
pro-inflammatory state may be considered limitations rather
advantages of this murine model.
LDLR/ mice are more moderate models of atherosclero-
sis compared to ApoE/mice. These mice gradually develop
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atherosclerotic lesions on a chow diet, which can be acceler-
ated by high fat feeding 166,183. In a closer approximation to
the human disease, the predominant lipoprotein in these mice
is LDL 166,183. LDLR deficiency in humans is the most com-
mon cause of familial hypercholesterolemia 188,189. The
LDLR/ model has been further manipulated to generate
mice that express only apoB100 190 or transgenic human
apoB100 191. In both cases, these mice develop accelerated
atherosclerosis on a standard chow diet 190,191.
In mice, atherosclerotic plaques predominantly develop in
the aortic sinus, aortic arch and brachiocephalic artery, in
contrast to human plaque, which primarily develops in the
carotid arteries, the coronary arteries and the aortic arch
16,166. Although significant insight into the initiating mecha-
nisms has been gained from mouse studies, it is noteworthy
that the progression, response to treatment and regression of
atherosclerotic plaque vary significantly between vascular
beds 192,193. Another important limitation of mouse models
is the rarity of advanced coronary lesions that progress to
rupture and thrombosis 166,194. This is a common complica-
tion of atherosclerosis in humans that cannot be modelled in
these animals.
One ethical and practical concern when designing exper-
iments involving high fat fed mice or ApoE/ mice is their
tendency to develop eruptive skin lesions and ulcerative der-
matitis 195,196. This is a source of significant pain and in-
flammation, and often requires premature humane
euthanasia 195,196.
Spontaneous atherosclerosis can occur in swine and rumi-
nant species 197–200. Experimental induction of this disease
has been performed in calves and goats, with reported char-
acteristics similar to human atherosclerosis 168,201,202. In a
study by Hines et al. (1985), young male goats were used
to assess the effects of dietary calcium and cholecalciferol
on plasma and tissue cholesterol concentrations, the distri-
bution of total lipid in the body, and aortic and plasma con-
centrations of calcium and magnesium 168. Outcomes of this
study found that this diet may not affect cholesterol and/or
total lipid metabolism. However, effects on deposition of
lipid and mineral in arterial walls were noted, and aortic cal-
cification, as well as lipid infiltration and plaque formation,
may predispose an individual to atherosclerosis 168. Whilst
the goat model may be of limited use because of the rela-
tively short amount of time for atherosclerosis to develop
compared to humans, further studies with the goat may con-
tribute to increased understanding of the mechanisms under-
pinning CVDs.
Pigs have also been used as a model for atherosclero-
sis 203–205. Atherosclerosis develops slower in pigs
compared to mice. Pigs also develop lesions spontaneously,
and in time, these lesions develop in the coronary vascula-
ture 75,206,207. Atherosclerosis can be induced in pigs through
an atherogenic diet 75,206,207. HF/HC fed pigs develop com-
plex atherosclerotic lesions that share many of the patholog-
ical features of human lesions, including smooth muscle
cells, inflammatory infiltrates, foam cells, fibrous caps, ne-
crotic and apoptotic cells, plaque haemorrhage, calcification
and expanded extracellular matrices 208–211. Anatomically,
the distribution of lesions in the pig is similar to humans,
and more importantly, these include a propensity for lesions
to develop in the coronary circulation 16,208–212. One pro-
posed reason for these similarities between man and
pig is the similarity of lipoprotein profile between the two
species 16,166. A recent study using young adult male pigs
fed on a high fat diet for 20–24weeks assessed the effects
of hypercholesterolaemia, with the aim to examine early
stage atherosclerosis 204. Significantly greater intima–media
thickness of the abdominal aorta, carotid artery and
femoral artery, indicated relatively rapid progression of ves-
sel disease 204. This is consistent with past reports in humans
demonstrating that increased thickness of the walls of the ab-
dominal aorta and carotid artery can independently predict ath-
erosclerosis, coronary artery disease, myocardial infarction
and stroke 213–216. Associations of CVD risk factors and events
have also been associated with increased intima–media thick-
ness of the femoral artery 217.
Spontaneous familial hypercholesterolemia has also been
reported in pigs 218,219. These pigs have the arg94 residue of
their LDLR substituted by a Cys resulting in a missense mu-
tation 220,221. These pigs have excessive circulating LDL
and reduced HDL, and as a result, they develop severe ath-
erosclerosis in the coronary and aortic arteries, even while
fed a standard pig diet 218,219. Transgenic familial hypercho-
lesterolaemia miniature pigs have also been produced in or-
der to evaluate atherosclerosis 222,223. These minipigs
recapitulate several of the features observed in human ath-
erosclerosis 223. An important translational feature of pig
models is the possibility of percutaneous coronary interven-
tion using human clinical equipment and stents 224–229. Fur-
thermore, pig models also develop restenosis 226,230, a
common complication of stent implantation that compro-
mises long-term outcomes 226. On the whole, the porcine
model has great potential in uncovering the more specific
details in atherosclerotic progression. The minipig is also
advantageous, as it requires lower maintenance costs com-
pared to larger animals.
DIABETES MELLITUS ACCELERATED
ATHEROSCLEROSIS
Cardiovascular complications are common in diabetes
mellitus (DM) patients and include cardiomyopathies and
accelerated atherosclerosis. DM patients are usually grouped
into two different types based primarily on aetiology. Type
1 DM (T1DM) is characterized by hyperglycaemia because
of a deficiency in insulin that is the result of autoimmune de-
struction of β-cells in the pancreas. Type 2 DM (T2DM), on
the other hand, is characterized by hyperglycaemia because
of insulin resistance. T2DM is typically preceded by a
hyperinsulinaemic euglycemic period. Glucotoxicity and
lipotoxicity in T2DM lead to progressive destruction of β–
cells, and ultimately hypoinsulinaemia. Commonly, T2DM
patients are also obese with some degree of dyslipidaemia.
T2DM accounts for 95% of DM patients and is more com-
monly associated with CVD than T1DM 169,170.
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Researchers have employed several approaches to de-
velop animal models of DM. These approaches are depen-
dent on the type of DM to be modelled. For T1DM, a
common approach is ablation of β-cells with pharmacologi-
cal agents, such as Alloxan and Streptozotocin (SZT), where
these chemicals are taken up by β-cells and induce free rad-
ical formation leading to cytotoxicity 231–234. SZT treatment
in wild type mice has been shown to induce
hyperglycaemia, but with a modest reduction in insulin
production 235. When fed a high fat diet, these mice show
increased size of fatty streaks 235,236. SZT treatment in
ApoE mice results in hyperglycaemia and insulin defi-
ciency 237,238. Hypercholesterolaemia in these mice is exac-
erbated by SZT. This increased cholesterol is primarily
VLDL and LDL. Of particular importance is the dramatic
increase in atherosclerotic lesion area in the SZT mice com-
pared to non-treated controls 237,239,240. The increase in ath-
erosclerosis in these animals has been attributed to
hyperglycaemia and the formation of advanced glycation
end products 237. Interestingly, SZT-treated LDLR mice dis-
play no differences in atherosclerosis development com-
pared to untreated LDLR mice 241. Pigs have also been
employed in studying the effects of DM on atherosclerosis.
Yucatan miniature pigs fed a high fat diet and treated with
Alloxan develop hypercholesterolaemia and insulin resis-
tance 242. When compared to high fat fed untreated pigs,
the high fat fed Alloxan-treated group showed significantly
increased coronary atherosclerosis 243. Similarly, Alloxan
treatment in conjunction with high fat feeding increased ath-
erosclerosis in Sinclair miniature pigs 76.
The models described above have provided important in-
sights into the effects of hyperglycaemia on atherosclerosis.
These models do however require some degree of β-cell re-
duction. This, depending on the degree of reduction, resem-
bles T1DM more than T2DM. A common method to induce
T2DM in animals is a dietary approach. For example, high
fat, but not high fructose, fed ApoE/ mice develop fasting
hyperglycaemia and hypoinsulinaemia consistent with
T2DM 244. These mice have significantly increased athero-
sclerosis compared to control diet ApoE/ mice 244. Simi-
larly, high fat, but not high fructose diet, induces diabetes
and increases atherosclerosis in LDLR/ mice 245.
Mice with impaired leptin signalling lack a sense of
satiety, and as a result are characterized by excessive feed-
ing and obesity. These mice readily develop insulin resis-
tance. Similar to high fat fed wild type mice, they do not
reliably develop atherosclerosis because of the majority of
their circulating cholesterol being HDL. To investigate the
effects of DM on atherosclerosis, LDLR/ mice have been
crossed with either leptin deficient mice (Lepob/ob) or leptin
receptor deficient mice (leprdb/db). These mice are obese
with hypercholesterolaemia because of both elevated LDL
and VLDL 246,247. These mice also have extensive spontane-
ous atherosclerotic lesions 247–251. The primary difference
between the two strains is ApoE/ leprdb/db have high cir-
culating leptin levels 252. Similarly, double knock out
ApoE/ Lepob/ob and ApoE/ leprdb/db are also obese with
hypercholesterolaemia and insulin resistance 252–254.
Atherosclerosis is accelerated and exacerbated compared to
ApoE/ only mice 252–255. Hypercholesterolaemia in these
mice is extreme, and concerns have been has raised over the
interpretation of results from these animals 256.
Ossabow pigs have a natural propensity for obesity 257.
When fed a high fat diet, these pigs develop obesity with de-
creased glucose tolerance and hyperinsulinaemia 258–260.
High fat feeding also induces hypercholesterolaemia with a
predominant increase in LDL cholesterol 259–261. Neointi-
mal hyperplasia and atherosclerosis are significantly in-
creased in the coronary circulation on these pigs 258,261.
Compared to Yucatan pigs, Ossabow pigs recapitulate more
closely the metabolic and cardiovascular phenotype of DM
and atherosclerosis 258.
ABDOMINAL AORTIC ANEURYSM (AAA)
Abdominal aortic aneurysm (AAA) is the tenth leading
cause of death in men above 60, with 6–9% of males over
65 year old being affected, and is becoming more common
in women 262. Clinical risk factors for AAA include ageing,
gender, hypertension, smoking and a family history of aneu-
rysm disease 262–265. However, the risk of smaller aneurysm
rupture in women is greater than in men 264. AAA involves
inflammatory cell infiltration, SMC apoptosis in the aortic
wall and ECM degradation 266.
As with many CVDs, the lack of samples from healthy or
early stage disease patients hinders research. Accordingly,
Riches et al. (2013) examined the biology of SMCs from
isolated porcine carotid arteries to assess the potential of this
model for AAA 263. Porcine arterial SMC samples exposed
to combined collagenase/elastase treatment in a bioreactor
share phenotypic features with cultured end-stage AAA hu-
man SMC samples 263. The study of SMCs from a large an-
imal source and the use of a bioreactor to maintain an
ex vivo model would be of value in studies of blood vessel
wall components in vascular disease.
CORONARY HEART DISEASE
Coronary heart disease (CHD) is the single most common
cause of cardiovascular-related deaths in Europe and the
USA, accounting for almost 380000 deaths in 2010 in the
USA, and around 74000 deaths in the UK 4,267,268. Various
large animal models have been generated through the induction
of coronary artery narrowing or occlusion. In a pig model of
atherosclerotic CHD the site and time point of coronary occlu-
sions were unpredictable and thus this model is inappropriate
for research into CHD-related heart failure, where it is impor-
tant to characterize the precise progression of the disease 267.
The response to injury in the coronary arteries of pigs is compa-
rable to that in the human 269,270. As the biological processes
seen in arterial repair are similar between the pig and human,
these pre-clinical studies are extremely valuable 6. Other
models of heart failure involve surgically constricting the coro-
nary arteries or artificially producing intracoronary embolisms.
This approach has been used in dogs and pigs (reviewed in 267).
123CARDIOVASCULAR DISEASE MODELS
2016 The Authors. Published by John Wiley & Sons Ltd. Cell Biochem Funct 2016; 34: 113–132.
FUTURE DIRECTIONS: POTENTIALS OF LARGE
ANIMAL TRANSGENIC MODELS
There is still much progress to be made in the field of CVDs,
and the generation of more suitable large animal models,
such as the pig, would be highly valuable in examining the
underlying processes that lead to the initiation and progres-
sion of this disease. As will be briefly commented on below,
the use of novel genetic engineering techniques may play a
role in furthering our understanding of CVDs.
USE OF TRANSGENIC TOOLS
Substantial progress has been made in the fields of genetic
manipulation and molecular cloning. These tools create a
large window of opportunities for creating refined models
for future biomedical research. Such models will facilitate
studying the pathophysiology of human diseases, and be in-
strumental in improving and developing new diagnostic
tests and therapeutic approaches.
Transgenic model systems have been established using
organisms like the fruit fly (Drosophila melanogaster),
rodents and zebrafish 271. Although these models are highly
informative, they do not sufficiently emulate the complexi-
ties of human biology. Consequently, the models of human
disease often do not adequately mimic the human condition.
There is now increased potential for genetically engineered
large animal models of human disease. In particular, the
pig is becoming an increasingly relevant model organism
for this approach to developing models. This is largely
because of closer similarities with humans in terms of
anatomy, genetics and physiology than the classical animal
models. Pigs are relatively easy to breed, produce large
litters, are available in a range of genotypes and
phenotypes and provide access for biopsies and post-mortem
samples 271. As mentioned previously, miniature pigs have
already proven to be valuable in biomedical research, includ-
ing the field of cardiovascular biology 222,223,272.
A major goal in biological research is to further our
understanding on the relationships between genotype and
phenotype. Traditional approaches in understanding gene
function have been restricted because of the lack of
required tools for gene customization 273. More recently
the possibilities of gene customization have expanded
rapidly through the development of new and innovative
technologies in the field of genome engineering, such as
the use of zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs) and clustered
regularly interspaced short palindromic repeats (CRISPRs).
These next generation technologies serve as powerful tools
for gene knock-out and targeted manipulation of genomes
(Figure 4).
Figure 4. TALEN or CRISPR/Cas9 systems of gene editing. After zygote injection of customized transcription activator-like effector nuclease (TALEN)
mRNA or Cas9 mRNA/single guide RNA (sgRNA), the gene of interest can be targeted and cut to produce a double strand break (DSB). TALENs work in
pairs as the FokI endonuclease requires dimerization in order to produce a DSB. Various CRISPR/Cas9 systems exist for different applications. Fundamentally,
the sgRNA directs the Cas9 nuclease to the site of targeting. After a DSB is created, DNA repair mechanisms occur via two main pathways: non-homologous
end joining (NHEJ) and homology directed repair (HDR). NHEJ leads to insertion/deletion mutations (indels), whilst HDR can be used to insert desired se-
quences. Through these mechanisms, an edited animal can be produced
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The first widely used genome editor was the ZFN 274 and
along with TALEN technology has been effective in ge-
nome editing of cultured cells and numerous species leading
to the production of transgenic rats, zebrafish, and pigs 275–
278. More recent to the TALEN editing platform, the
CRISPR and Cas9 (the latter of which is a class of RNA-
guided endonuclease) system is rapidly evolving as a novel
genome editing technology 279. This is due its ability to
achieve precise genome editing to induce the specific muta-
tions that have been observed in human patients, in a man-
ner that leaves no molecular footprint within the target
genome.
The CRISPR/Cas9 technology has also been used in
large animals. Gene knockout in goats has achieved an
efficiency of 9–70% of induced mutations in primary
fibroblasts, with success in generating cloned goats with
bi-allelic mutations, although cloning efficiency was low
(1.1%), similar to other groups 280,281. CRISPR/Cas9 has
also been used in pigs, where the von Willebrand factor
(vWF) gene, whose deficiency causes severe von
Willebrand disease in humans, was targeted 282. In this
study, 68% piglets born through zygote injection had
edited genomes, with 55% of these bearing bi-allelic
mutations and 45% with mono-allelic mutations 282. The
overall high birth and survival rates indicate little toxicity
from injecting with Cas9 mRNA and single guide RNA
(sgRNA) 282. These studies demonstrate that this trans-
genic tool can be used in livestock species, and can con-
tribute to numerous applications of large animals in
biomedical research.
There are limitations to the use of transgenic models, be-
cause of the present lack of information on the molecular bi-
ology of large mammalian organisms. Recent efforts have
been dedicated to characterising these animals at the molec-
ular level, for example in terms of their genomics, tran-
scriptomics and proteomics. The pig genome has been
extensively sequenced 283 as has the sheep genome 284. In-
formation is also available for the genomes of dog, cat, bo-
vine, horse, guinea pig and rabbit (see http://www.ensembl.
org), all of which can provide natural or transgenic
models for human CVD. Although the gene annotation
and assembly of the porcine genome are incomplete, geno-
mic comparisons between the pig and human do demon-
strate more structural resemblance than between mice and
human 285,286. Transcriptomic analysis of pig RNA also
shows greater similarity with human than does mouse 287.
With the combination of innovative and efficient transgenic
tools coupled with biologically relevant models of human
diseases, there is little doubt that major advances in the car-
diovascular field will be made in the areas of drug discov-
ery, and targeted therapies for CVDs.
CONCLUSIONS
Large animal models of human disease are valuable re-
sources for identifying and gaining knowledge on the under-
lying factors in the progression of CVDs and the
mechanisms of action. Understanding the critical molecular
processes and the role of fundamental drivers that lead to
CVDs is important in ensuring successful outcomes of inter-
ventional and therapeutic approaches. With the advance-
ments of state-of-the-art genome editing technologies like
TALENs and CRISPRs, customisable models can be devel-
oped, which will greatly enhance the field of cardiovascular
research. This can allow for more translational research po-
tentially leading to treatments for human cardiovascular dis-
orders, both congenital and acquired.
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